COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

OBJECTIVE: To estimate risks for all‐cause mortality and for severe COVID‐19 in multiple sclerosis patients and across relapsing–remitting multiple sclerosis patients exposed to disease‐modifying therapies. METHODS: We conducted a Swedish nationwide population‐based multi‐register linkage cohort stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Longinetti, Elisa, Bower, Hannah, McKay, Kyla A, Englund, Simon, Burman, Joachim, Fink, Katharina, Fogdell‐Hahn, Anna, Gunnarsson, Martin, Hillert, Jan, Langer‐Gould, Annette, Lycke, Jan, Nilsson, Petra, Salzer, Jonatan, Svenningsson, Anders, Mellergård, Johan, Olsson, Tomas, Piehl, Fredrik, Frisell, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463950/
https://www.ncbi.nlm.nih.gov/pubmed/35993445
http://dx.doi.org/10.1002/acn3.51646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463950/
https://www.ncbi.nlm.nih.gov/pubmed/35993445
http://dx.doi.org/10.1002/acn3.51646

Ejemplares similares